CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. is listed today as CytomX Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
Funding rounds of CytomX Therapeutics, Inc.| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|
| Jun 2023 | $30 M | Private placement after listing | $10 to $50 million | | options | SEC |
| Jun 2015 | $70 M | No. 3 | $50 to $250 million | | equity | SEC |
| Dec 2014 | $17 M | No. 2 | $10 to $50 million | | equity | SEC |
| Jul 2012 | $13 M | No. 1 | $10 to $50 million | | equity | SEC |
What its filings and its own website say, sentence by sentence, each with its source.
CytomX Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2023).
SEC Form D · Aug 2023
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2023
No products or services of CytomX Therapeutics, Inc. are on record.
11 named in official filings. Open an investor to see everything it has backed.
Investors in CytomX Therapeutics, Inc.| Investor | Kind | Amount | Round | Role | Source |
|---|
| Canaan IX L.P. | Fund or asset manager | not stated | not stated | Held Series B-1 and C preferred stock, 10% owner, director (Form 3, 2015) | SEC Form 3 |
| Canaan Partners IX LLC | Fund or asset manager | not stated | not stated | Held Series B-1 and C preferred stock, 10% owner, director (Form 3, 2015) | SEC Form 3 |
| Deerfield Management Company, L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Mgmt III, L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Mgmt L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Private Design Fund III, L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Special Situations Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Hadley Harbor Master Investors (Cayman) L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Third Rock Ventures GP, L.P. | Venture capital | not stated | not stated | Held Series B-1 and C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Third Rock Ventures LP | Venture capital | not stated | not stated | Held Series B-1 and C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| TRV GP, LLC | Other | not stated | not stated | Held Series B-1 and C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
Largest shareholders today
Institutions holding CytomX Therapeutics, Inc. shares, as of Sep 30, 2026.
As of Sep 30, 2026
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
People named by CytomX Therapeutics, Inc.| Name | Role | Named in |
|---|
| Chris Ogden | Executive officer | Aug 2023 |
| Jeff Landau | Executive officer | Aug 2023 |
| Lloyd Rowland | Executive officer | Aug 2023 |
| Marcia Belvin | Executive officer | Aug 2023 |
| Sean McCarthy | Executive officer | Aug 2023 |
| Wayne Chu | Executive officer | Aug 2023 |
| Fletcher W. Payne | Executive officer | Aug 2012 |
| Alan Ashworth | Director | Aug 2023 |
| Elaine Jones | Director | Aug 2023 |
| Halley Gilbert | Director | Aug 2023 |
| James Meyers | Director | Aug 2023 |
| Mani Mohindru | Director | Aug 2023 |
| Matthew Young | Director | Aug 2023 |
| Sean McCarthy | Director | Aug 2023 |
| Elaine V. Jones | Director | Jun 2015 |
| Frederick W. Gluck | Director | Jun 2015 |
| Hoyoung W. Huh | Director | Jun 2015 |
| Neil W. Exter | Director | Jun 2015 |
| Rachel V. Humphrey | Director | Jun 2015 |
| Tim W. Shannon | Director | Jun 2015 |
| Charles W. Homcy | Director | Aug 2012 |
Went public since 2015. Its SEC number is that of a company listed on a stock exchange.